Pelthos Therapeutics Inc.
PTHS evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for PTHS—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · PTHS
Pelthos Therapeutics Inc. (PTHS) is a commercial-stage biopharmaceutical company focused on dermatologic and pain therapies, with one marketed product (Zelsuvmi) and two recently acquired FDA-approved products (Xepi, Xeglyze).
Key risk: Going concern risk
BioSniper Score
Based on 6 of 6 signals
Market Cap
$94.7M
Cash Runway
14.1 moLead Asset
cc8464 (Phase 1)
Next Catalyst
Patent_Expiry · Jan 29, 2032Financial data as of Jun 30, 2026.
Tracking 6 pipeline candidates · 3 catalysts for Pelthos Therapeutics Inc..
Pelthos Therapeutics Inc. (PTHS) is a commercial-stage biopharmaceutical company focused on dermatologic and pain therapies, with one marketed product (Zelsuvmi) and two recently acquired FDA-approved products (Xepi, Xeglyze).
- Lead commercial product Zelsuvmi generated net product revenues of $26.1M for the six months ended June 30, 2026 [sec_mda · as of 2026-08-13].
- Cash and equivalents of $24.2M as of June 30, 2026, with working capital of $31.4M [sec_mda · as of 2026-08-13].
- Net loss of $23.4M for the six months ended June 30, 2026, and an accumulated deficit reflected in negative shareholders' equity of -$6.5M [latest reported financials as of 2026-06-30].
- Total debt of $43.3M as of June 30, 2026, including a $50M venture loan facility entered in January 2026 [sec_mda · as of 2026-03-19].
- Quarterly Zelsuvmi revenues have grown sequentially from $7.1M (Sep 2025) to $15.4M (Jun 2026) [sec_mda · as of 2026-08-13].
What works
- Zelsuvmi revenue is growing quarter over quarter, from $7.1M in Q3 2025 to $15.4M in Q2 2026, indicating commercial traction [sec_mda · as of 2026-08-13].
- The company has expanded its commercial portfolio by acquiring two additional FDA-approved products (Xepi and Xeglyze) in Q4 2025, diversifying revenue sources [sec_mda · as of 2026-03-19].
- A $50M venture loan facility provides additional capital to support commercialization and operations [sec_mda · as of 2026-03-19].
What to weigh
- The company has a history of net losses and negative shareholders' equity, with a net loss of $23.4M in the first half of 2026 [latest reported financials as of 2026-06-30].
- Management previously expressed substantial doubt about the company's ability to continue as a going concern, though conditions have been alleviated by recent financing [sec_mda · as of 2026-03-19].
- Total debt of $43.3M as of June 30, 2026, adds financial leverage and interest obligations [latest reported financials as of 2026-06-30].
- The company will need additional capital to expand its pipeline or pursue acquisitions, and future capital requirements depend on uncertain factors such as Zelsuvmi sales and competition [sec_mda · as of 2026-08-13].
From the filings
Quoted directly from source documents.
Zelsuvmi revenue growth
“For the six months ended June 30, 2026, the Company recorded net product revenues in the amount of $26.1 million for its lead commercial product, Zelsuvmi.”
SEC MD&A · August 13, 2026
Cash position and working capital
“As of June 30, 2026, the Company had cash of approximately $24.2 million and working capital of $31.4 million.”
SEC MD&A · August 13, 2026
Venture loan facility
“The Venture Loan and Security Agreement provides for a senior secured term loan facility in an aggregate principal amount of up to $50.0 million.”
SEC MD&A · March 19, 2026
Catalyst timeline
- 2032-01-29 · Patent_Expiry · XEPI — Patent/Exclusivity Expiry: XEPI — Patent expiry for Xepi could open the product to generic competition, affecting future revenue.
- 2034-12-17 · Patent_Expiry · XEGLYZE — Patent/Exclusivity Expiry: XEGLYZE — Patent expiry for Xeglyze may lead to generic entry, impacting long-term sales.
- 2035-07-10 · Patent_Expiry · ZELSUVMI — Patent/Exclusivity Expiry: ZELSUVMI — Patent expiry for Zelsuvmi could reduce market exclusivity and revenue potential.
Risks & what to watch (4)›
Key risks
- Going concern risk — Management previously disclosed substantial doubt about ability to continue as a going concern, alleviated by recent financing [sec_mda · as of 2026-03-19].
- Negative equity and losses — Shareholders' equity of -$6.5M and net loss of $23.4M in H1 2026 indicate ongoing financial strain [latest reported financials as of 2026-06-30].
- Debt burden — Total debt of $43.3M as of June 30, 2026, increases fixed obligations and financial risk [latest reported financials as of 2026-06-30].
- Dependence on Zelsuvmi — Future capital requirements depend on Zelsuvmi sales, which face competition and market adoption risks [sec_mda · as of 2026-08-13].
What to watch
- Quarterly Zelsuvmi revenue trends to assess commercial momentum [sec_mda · as of 2026-08-13].
- Ability to achieve milestones for the remaining $20M of the venture loan facility [sec_mda · as of 2026-03-19].
- Progress on integrating and commercializing acquired products Xepi and Xeglyze [sec_mda · as of 2026-03-19].
- Any updates on the NaV1.7 pain program pipeline [sec_mda · as of 2026-03-19].
Sources: SEC filings · SEC MD&A · Generated August 20, 2026 · How we verify sources →
Run Pelthos Therapeutics Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Pelthos Therapeutics Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 6 of 6 signals · derived from public data
14.1 months
OCF -$8M · Net income -$23M
Lead: Approved
6 candidates
3 upcoming, next in ~1978d
2 buys · 17 sells (180d)
Runway
Catalysts
Pipeline
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
14
Total value held
$9.2M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 186,186 | $3.9M |
| boothbay fund management, llc | 81,858 | $1.7M |
| j. goldman & co lp | 50,415 | $1.1M |
| cantor fitzgerald, l. p. | 41,423 | $870K |
| diadema partners lp | 24,773 | $520K |
| knott david m jr | 21,073 | $443K |
| geode capital management, llc | 15,290 | $321K |
| vanguard fiduciary trust co | 9,817 | $206K |
| persistent asset partners ltd | 6,007 | $126K |
| steward partners investment advisory, llc | 1,910 | $40K |
Showing top 10 of 14 institutional holders of Pelthos Therapeutics Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 30, 2026- % of float
- 2.9%
- Days to cover
- 4.7
- Shares short
- 45,956
- Daily short volume (Jun 26, 2026)
- 83.2%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
PTHS short interestGovernance
Frequently asked questions
What is the AI investment thesis for Pelthos Therapeutics Inc.?
Pelthos Therapeutics Inc. (PTHS) is a commercial-stage biopharmaceutical company focused on dermatologic and pain therapies, with one marketed product (Zelsuvmi) and two recently acquired FDA-approved products (Xepi, Xeglyze).
What is Pelthos Therapeutics Inc.'s lead drug candidate?
Pelthos Therapeutics Inc.'s most advanced tracked candidate is cc8464 (Phase 1) for Neuropathic pain, specifically Erythromelalgia (EM) and idiopathic small fiber neuropathy (iSFN).
What is Pelthos Therapeutics Inc.'s next catalyst?
Pelthos Therapeutics Inc.'s next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: XEPI" — expected January 29, 2032.
Who is the CEO of Pelthos Therapeutics Inc.?
Mr. Scott M. Plesha is the chief executive officer of Pelthos Therapeutics Inc. (PTHS).
Where is Pelthos Therapeutics Inc. headquartered?
Pelthos Therapeutics Inc. (PTHS) is headquartered in Durham, NC, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.